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K+ channel blockers like 3,4-diaminopyridine (DAP) can double isometric muscle force.
Functional movements require more complex concentric and eccentric contractions, how-
ever the effects of K+ channel blockade on these types of contractions in situ are unknown.
Extensor digitorum longus (EDL) muscles were stimulated in situ with and without DAP
in anesthetized rats and fatigability was addressed using a series of either concentric or
eccentric contractions. During isotonic protocols (5–100% load), DAP significantly shifted
shortening- and maximum shortening velocity-load curves upward and to the right and
increased power and work. Maximum shortening, maximum shortening velocity, and
power doubled while work increased by ∼250% during isotonic contraction at 50% load.
During isotonic fatigue, DAP significantly augmented maximum shortening, work, short-
ening velocity, and power. During constant velocity eccentric protocols (2–12 mm/s), DAP
increased muscle force during eccentric contractions at 6, 8, 10, and 12 mm/s. During
eccentric contraction at a constant velocity of 6 mm/s while varying the stimulation fre-
quency, DAP significantly increased muscle force during 20, 40, and 70 Hz. The effects
of DAP on muscle contractile performance during eccentric fatigue varied with level of
fatigue. DAP-induced contractile increases during isotonic contractions were similar to
those produced during previously studied isometric contractions, while the DAP effect dur-
ing eccentric contractions was more modest. These findings are especially important in
attempting to optimize functional electrical stimulation parameters for spinal cord injury
patients while also preventing rapid fatigue of those muscles.
Keywords: 3,4-diaminopyridine, eccentric contraction, isotonic contraction, EDL, fatigue
INTRODUCTION
The fundamental strategy for successful functional neuromuscular
stimulation of skeletal muscles is the use of stimulation paradigms
which maximize muscle force yet minimize muscle fatigue. One
common strategy has been to use variable frequency train stim-
ulation, in which a brief high frequency burst precedes a lower
frequency stimulus train, thereby eliciting the catch-like property
of muscle (Binder-Macleod and Barrish, 1992; Binder-Macleod
et al., 1998; Bigland-Ritchie et al., 2000; van Lunteren and Sankey,
2000). Unfortunately, this approach has not been very successful
in clinical use due to only modest force increases.
Another approach is to pharmacologically increase the input-
output relationship of skeletal muscle, for example by modulating
membranous K+ channel conductances. K+ channels control both
resting membrane potential and action potential duration, and
thereby are regulators of muscle contractile performance. Of the
multiple types of K+ channels present in muscle, voltage-gated
delayed rectifier K+ channels play the most important roles in
muscle contractile performance. Among the aminopyridines, DAP
is the preferred agent due to greater potency as a K+ channel
blocker, larger augmentation of muscle force in vitro, and reduced
crossing of the blood-brain barrier hence smaller potential for
neurologic side effects when used in vivo (Lundh et al., 1984;
McEvoy et al., 1989; Sanders et al., 2000). In humans, DAP has
been administered both orally and intravenously to treat Lambert–
Eaton myasthenic syndrome, myasthenia gravis, and multiple
sclerosis (Lundh et al., 1984, 1985; Sheean et al., 1988; McEvoy
et al., 1989; Bever et al., 1990; Sanders et al., 2000). K+ chan-
nel blockers, like 3,4-diaminopyridine (DAP), augment isometric
force in vitro and in situ (Miledi et al., 1977; Delbono and Kotsias,
1987; Lin-Shiau et al., 1991; van Lunteren and Moyer, 1996, 1998;
van Lunteren et al., 2006, 2008; Ionno et al., 2008; van Lunteren and
Pollarine, 2010). In previous in vitro studies, the maximum DAP-
induced extensor digitorum longus (EDL) twitch force increase
was 94± 12% (van Lunteren et al., 2006).
Due to its effects on muscle force in vitro, the use of the K+
channel blocker DAP appears to be an attractive approach to
improve muscle contractile performance for in vivo applications
and functional electrical stimulation paradigms in which high
force levels are needed. However, many functional movements
involve combinations of isometric, concentric, and/or eccentric
contractions. An example of an upper extremity FES application
is drinking. Raising the cup requires muscle shortening, holding
the cup while drinking requires muscle force generation keeping
muscle length constant, and lowering the cup back down requires
lengthening contractions. An example of a lower extremity FES
application is standing up, maintaining the standing position,
and then sitting back down. Standing up requires shortening
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contractions, remaining standing requires isometric contractions,
and sitting back down requires lengthening contractions. Walking
involves predominantly shortening and isometric contractions,
although lengthening contractions become more prominent dur-
ing downstepping (Newham et al., 1983a,b) and downhill motion
(Vihko et al., 1979; Armstrong et al., 1983a,b). Isometric, con-
centric, and eccentric contractions differ from each other with
regards to cellular energetics and actin-myosin cross-bridge for-
mation. It is already known that lengthening contractions result in
a high incidence of contraction-induced injury, particularly more
injurious than shortening contractions (McCully and Faulkner,
1985; Faulkner et al., 1989). Therefore, the likelihood of differ-
ing muscle contractile improvements to ion channel alterations
through the use of a K+ channel blocker like DAP is quite high.
Also the implications on the maintenance of any elevated force
throughout a fatigue protocol are that the eccentric contractions
would be less efficient. There are extensive data on aminopyridines
and isometric contractions (van Lunteren and Moyer, 1996, 1998;
van Lunteren et al., 2006, 2008; Ionno et al., 2008; van Lunteren
and Pollarine, 2010), limited data on isotonic contractions (but
only in vitro; van Lunteren and Pollarine, 2010), and no data on
eccentric contractions.
The primary purpose of these studies is to pharmacologically
increase the muscle force output during concentric and eccentric
contractions using the K+ channel blocker, DAP. The secondary
purpose of these studies is to verify that these force increases
are maintained throughout a period of fatiguing stimulation. We
hypothesize that the potential muscle damage due to eccentric
contraction will cause DAP-induced increases in muscle contrac-
tile performance to be less than that found previously during
isometric and isotonic muscle contraction. Since fatigue occurs
more rapidly in vitro than in situ, we hypothesize that the mus-
cle contractile increases in situ will be maintained for a longer
period of time than that during the in vitro study. However,
we also expect that DAP-induced inotropic effects during repet-
itive isotonic and eccentric stimulation will be shorter than that
seen during isometric contraction in situ due to increased energy
demands.
MATERIALS AND METHODS
All studies were approved by the Institutional Animal Care and
Use Committee and complied with NIH animal care guidelines.
We used the fast-twitch EDL muscle preparation used previ-
ously in our lab (van Lunteren et al., 2008) and modified from
Koh and Brooks (2001), in which the peroneal nerve was stimu-
lated to induce contraction of the intact EDL muscle. A total of 39
rats (373± 14 g) were anesthetized with an initial 0.6 ml/kg dose
of intraperitoneal ketamine (42.9 mg/ml), xylazine (8.6 mg/ml),
and acepromazine (1.4 mg/ml) mixture, with supplemental doses
given intraperitoneally or intravenously as needed throughout
the experiment. The rats were placed on a heated blanket and
maintained at a temperature of 37˚C by monitoring with a rec-
tal temperature probe. The distal tendon of the EDL was isolated
and tied with silk thread. The hindlimb was stabilized by pinning
the knee between sharpened screws and securing the foot. The
EDL tendon was attached to the lever arm of a dual-mode servo-
controlled force transducer (model 305B-L, Aurora Scientific, ON,
Canada) which was controlled by a computer using a data acquisi-
tion program [Dynamic Muscle Control (DMC) Software, Aurora
Scientific]. The Aurora Scientific lever system is able to operate in
force-controlled or length-controlled mode so that the muscle can
be stimulated in strictly isotonic, eccentric, or isometric contrac-
tions depending on the instrument settings (Watchko et al., 1997;
Pollarine et al., 2007; Munkvik et al., 2008; Till et al., 2008; van Lun-
teren and Pollarine, 2010). The peroneal nerve was isolated and
stimulated (pulse duration 0.2 ms) with a modified subminiature
electrode (Harvard Apparatus, Holliston, MA, USA). The voltage
used was 1.2 times that needed to achieve maximal twitch tension.
Prior to the start of the protocols, using a single muscle twitch, the
muscle length was adjusted to achieve maximal isometric twitch
tension (L0) and kept there for the remainder of the study.
The sub-maximal tetanic force during 20–40 Hz stimulation
(depending on the subsequent protocol) was determined and this
value was used to calculate the percentage load when the muscle
was subsequently stimulated at the respective frequency. Isomet-
ric baseline twitches were evoked at 0.1 Hz and muscle force was
recorded for a period of 3 min in order to monitor muscle stabil-
ity and also to provide a baseline force value for normalization.
Muscles that were randomly assigned to the control or DAP treat-
ment groups had an average baseline force of 63± 4 and 67± 3 g,
respectively, and were not significantly different (P = 0.40). Saline
(control) or DAP in saline (0.2 ml, 10 mg/kg) was infused intra-
venously via the jugular vein over∼2 min, which is the same dose
used in our previous in situ study of DAP and isometric contrac-
tions (van Lunteren et al., 2008). The optimal dose for eccentric
and isotonic contractions could have been altered slightly from
the optimal dose determined previously for isometric contrac-
tions. Isometric twitches were evoked at 0.1 Hz over 30 min. This
incubation period was followed by either an isotonic or an eccen-
tric protocol. Separate muscles were tested for each protocol in
the absence and presence of DAP, so that drug and no drug data
were obtained from muscle samples which underwent identical
stimulation paradigms.
ISOTONIC PROTOCOLS
The subset of muscles undergoing the isotonic experiments, sub-
sequently underwent one of two protocols. (1) DAP Effects on
Shortening-load curve (n= 5, 5). Isotonic trains were evoked at
20 Hz and 1 train/min at 5–100% load (no DAP) and 5–200%
load (DAP). (2) DAP effects on Shortening During Fatigue (n= 6,
8). Isotonic 40 Hz trains with a load of 40% (train duration 333 ms,
1 train/1.5 s) were evoked for a 300 cycles. The load percentages
were calculated based on the maximum load in the absence of
DAP.
Medium-range frequencies of 20–40 Hz were chosen because
DAP has no effect on isometric force at high frequencies (Del-
bono and Kotsias, 1987; Lin-Shiau et al., 1991; van Lunteren and
Moyer, 1996, 1998; van Lunteren et al., 2006, 2008). In prelimi-
nary experiments of fatigue during 20 Hz stimulation the amount
of tetanic fusion decreased considerably during the course of
repetitive stimulation, which impaired calculations of shortening
velocity. We chose a stimulation frequency of 40 Hz for the isotonic
fatigue experiments because this improved the duration of time
over which the contractions were sufficiently fused to measure
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FIGURE 1 | Effects of DAP on muscle shortening (A) and work (B) during 20 Hz isotonic stimulation at different loads. Load values were calculated as a
function of the maximum load before the addition of DAP (or no drug). Values are means±SE.
shortening velocity. The 40% load was chosen because this was the
minimum load which produced the maximum amount of work,
based on the results from a preliminary load curve.
ECCENTRIC PROTOCOLS
The subset of muscles undergoing the eccentric experiments sub-
sequently underwent one of three protocols. (1) DAP effects on the
force-velocity curve (n= 7, 7). Thirty Hertz trains were evoked at
1 train/min. For the first 300 ms of each 500 ms train, the length
was not changed. During the remaining 200 ms of each stimulus
train, the muscle was lengthened at a velocity of 2–12 mm/s. We
chose a stimulation frequency of 30 Hz based on preliminary stud-
ies indicating that this was the frequency that caused the greatest
force increase during eccentric contractions. (2) DAP effects on the
force-frequency curve (n= 7, 7). Trains were evoked at 1 train/min
at frequencies from 1 to 70 Hz with eccentric lengthening contrac-
tions at a velocity of 6 mm/s for 0.2 s (eccentric protocol similar to
that described above). (3) DAP effects on force during fatigue (n= 5,
5). Thirty Hertz eccentric trains lengthened at 6 mm/s (eccen-
tric protocol similar to that described above) at a frequency of 1
train/1.5 s were evoked for a period of 30 min.
ANALYSIS
The Dynamic Muscle Analysis (DMA) High Throughput com-
puter program (Aurora Scientific, ON, Canada) was used to
measure EDL force and length changes. Muscle performance was
evaluated by measuring work and power. Work was calculated as
the product of the isotonic afterload and the total amount of short-
ening. Power was calculated as the product of the isotonic afterload
(the product of the load applied to the muscle) and shortening
velocity, with velocity measured during the early portion of the
contraction (first 5 ms) when it was at or near its maximal value
(Pollarine et al., 2007). The power data are normalized to muscle
cross sectional area (muscle mass/muscle length×muscle spe-
cific gravity, assuming a muscle density of 1.06 g/ml; Close, 1972).
The maximal unloaded shortening velocity (V max) was calculated
based on Hill’s equation (Hill, 1938; Hatcher and Luff, 1985; Pol-
larine et al., 2007) by separately fitting each muscle velocity of
shortening curve to Hill’s equation, determining each separate
V max and then calculating the average of all the muscles. All data
were expressed as mean± SE. Force values were normalized to
the force during the pre-drug/pre-fatigue baseline period in order
to correct for slight variations in rat (and EDL) size. Statistical
analysis was done using repeated measures analysis of variance
followed by Newman–Keuls test in the event of statistical signifi-
cance. Two-tailed probability values of P ≤ 0.05 were considered
significant.
RESULTS
ISOTONIC CONTRACTIONS
Data for shortening, work, velocity of shortening, and power
were calculated as a function of the maximum load before the
addition of DAP (or no drug; Figures 1 and 2). The maximum
load was increased substantially by DAP which accounts for load
www.frontiersin.org September 2012 | Volume 3 | Article 383 | 3
van Lunteren and Moyer DAP effects on lengthening and shortening contractions
FIGURE 2 | Effects of DAP on muscle velocity of shortening (A) and power (B) during 20 Hz isotonic stimulation at different loads. Load values were
calculated as a function of the maximum load before the addition of DAP (or no drug). Values are means±SE.
percentages greater than 100% in the DAP-treated muscles (two-
way repeated measures ANOVAs were performed only on match-
ing data sets: load 5–100%). Values for maximum shortening
and work are depicted in Figure 1. DAP shifted the relation-
ship between shortening and load upward and to the right at
all loads and was significantly increased at all loads except 100%
(Figure 1A). In contrast, the effect of DAP on work varied with
the load (Figure 1B). At low loads the work done by the DAP-
treated muscle was nearly at the level of untreated muscle, but as
the load increased the work done by the DAP muscle augmented
to a significantly greater extent than that of the control muscle.
Further increases in load resulted in declines in work for both
groups, but the declines were right shifted for DAP-treated com-
pared with control muscle. Finally at near-maximum loads, work
was comparable for control and DAP-treated muscles.
The maximum shortening velocity curves were similar to the
maximum shortening curves in that DAP shifted the curve upward
and to the right at all loads, however not to the level of significant
difference (P = 0.066; Figure 2A). The graph of power vs. load of
control and DAP-treated muscles was similar in many respects to
the graph of the work vs. load in that DAP did not affect power at
low loads but significantly increased power at intermediate loads
(Figure 2B). In contrast to work, however, power of the DAP mus-
cles did not decrease to the level of the control muscles at very high
loads. The upward shifts of the DAP relative to no drug curves were
still present even when the work and power curves are plotted as a
function of post-DAP load (data not shown).
The average V max values were not significantly different
between no drug and DAP (P = 0.33), however, the DAP values
tended to be higher than control (824± 144 vs. 640± 104 mm/s,
respectively). The control V max value corresponds to 21 fiber
lengths per second and this value is similar to that previously
reported (20.6 fiber lengths per second) for an in situ EDL rat
muscle (Ranatunga and Thomas, 1990).
Figure 3 shows an example of muscle shortening during inter-
mittent train stimulation at 40 Hz. The DAP traces indicate consid-
erably improved contractile performance compared with control
traces during the 1st, 50th, and 100th train. The maximum short-
ening of DAP-treated muscles was significantly greater than that of
control muscles for the first 140 trains of isotonic fatiguing stim-
ulation (Figure 4A). In addition, the work done after the addition
of DAP during 40 Hz intermittent fatiguing stimulation was sig-
nificantly greater than that after the addition of no drug during the
1st through 30th train and 60th through 120th train (Figure 4B).
Untreated muscle had minimal shortening and work during the
second half of the fatigue testing, whereas DAP-treated muscle
maintained contractile performance during the same time period
(Figure 4).
Shortening velocity and power were measured and calculated
only during the first 60 trains of 40 Hz intermittent fatiguing stim-
ulation because EDL muscle contraction trains became sufficiently
unfused that shortening velocity (and thus also power) was not
able to be measured accurately. Shortening velocity and power
were both significantly greater with than without DAP throughout
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FIGURE 3 | Examples of muscle shortening during trains 1, 50, and 100
during 40 Hz intermittent isotonic contractions with and without DAP.
FIGURE 4 | Effects of DAP on maximum shortening (A) and work (B)
during 40 Hz isotonic contraction at 40% load over the first 60 trains.
Values are means±SE.
all (shortening velocity) or most (power) of the 60-train repetitive
stimulation period (Figures 5A,B).
ECCENTRIC CONTRACTIONS
Eccentric contractions were assessed in separate animals than
the above-described isotonic contractions. EDL muscles were
lengthened by various amounts while being stimulated at 30 Hz,
and the resulting muscle force during the lengthening portion of
the contraction was measured to assess muscle contractile per-
formance during eccentric contractions (Figure 6). The force
produced after the addition of DAP was significantly greater than
that during control conditions when muscle was lengthened by
1.2, 1.6, 2.0, and 2.4 mm when force was expressed as a percent of
the initial pre-drug isometric twitch force (Figure 6).
Muscles were also stimulated at various frequencies while the
amount of lengthening was constant (1.2 mm), and the resulting
muscle force is depicted in Figures 7 and 8. Figure 7 is an example
of the eccentric contractions. After the first 300 ms of the 500 ms–
30 Hz train, the muscle length was changed at a velocity of 6 mm/s.
Muscle force was significantly greater with the addition of DAP at
frequencies of 20, 30, and 40 Hz when calculated as a percent of
initial force (Figure 8).
Eccentric fatigue testing was done during stimulation at 30 Hz
while lengthening the muscle by 1.2 mm (Figure 9). The initial
30 Hz muscle force was significantly greater with DAP than with-
out. Second, the control muscles exhibited a larger amount of
force potentiation than the DAP muscles. After the 10th cycle, the
potentiation resulted in a significantly higher control muscle force
than the DAP muscle force (Figure 9). Third, the control muscle
force remained significantly higher than that of DAP muscle force
until the 100th cycle, when it had decreased to levels that were no
longer significantly different than that of DAP muscle force.
DISCUSSION
During isotonic contractions, maximum shortening, maximum
shortening velocity, and power doubled while work increased by
∼250%. These parameters remained augmented throughout the
period of 40 Hz isotonic fatigue. During eccentric contraction,
DAP significantly increased muscle force during 20, 40, and 70 Hz.
However, the effects of DAP on muscle contractile performance
during eccentric fatigue varied with level of fatigue. DAP-induced
contractile increases during isotonic contractions were similar
to those produced during previously studied isometric contrac-
tions, while the DAP effect during eccentric contractions was more
modest.
Many types of K+ channels are present in mammalian skele-
tal muscle which control both resting membrane potential and
action potential duration, and thereby are key regulators of muscle
contractile performance. The findings of this study are espe-
cially important in attempting to optimize functional electrical
stimulation parameters for spinal cord injury patients while also
preventing rapid fatigue of those muscles.
The present study utilized intermediate stimulation frequen-
cies for this study because augmentation of isotonic contractile
performance with DAP was documented at low to intermedi-
ate stimulation frequencies in previous in vitro studies (Miledi
et al., 1977; Delbono and Kotsias, 1987; Lin-Shiau et al., 1991; van
Lunteren and Moyer, 1996, 1998; van Lunteren et al., 2006, 2008;
Ionno et al., 2008; van Lunteren and Pollarine, 2010). In addition,
we have consistently found that DAP and the closely related 4-
aminopyridine do not improve isometric force at high stimulation
frequencies either in situ or in vitro (van Lunteren et al., 1995, 2006,
2008; van Lunteren and Moyer, 1996, 1998; van Lunteren, 1999;
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FIGURE 5 | Effects of DAP on shortening velocity (A) and power (B) during 40 Hz isotonic contraction at 40% load over the first 60 trains. Values are
means±SE.
Ionno et al., 2008; van Lunteren and Pollarine, 2010). Most impor-
tantly, almost all functional neuromuscular stimulation paradigms
use low to intermediate rather than high stimulation frequencies
for restorative tasks.
The lack of force increase produced by the aminopyridines
at high stimulation frequencies potentially limits their clinical
utility for muscle weakness due to primary muscle disease. How-
ever, during functional neuromuscular stimulation applications
designed to restore motor activity in subjects with spinal cord
injuries, modest rather than high stimulation frequencies are fre-
quently used (Glenn et al., 1988; Bhadra and Peckham, 1997).
Some restorative applications are currently limited by the need to
generate high force values while at the same time avoiding muscle
fatigue, in particular for weight-bearing activities such as stand-
ing up from a seated position, maintaining a standing posture,
and walking. Several electrical stimulation paradigms have been
devised to optimize the input-output relationship of skeletal mus-
cle, such as variable frequency stimulation (Burke et al., 1970, 1976;
Binder-Macleod and Barrish, 1992; Bigland-Ritchie et al., 2000),
but this has had limited clinical effectiveness in human functional
neuromuscular stimulation applications due to relatively modest
force increases, in particular when compared with the force aug-
mentation that can be achieved with pharmacological agents like
DAP.
These complex functional tasks often involve shortening con-
tractions and lengthening contractions in addition to static con-
tractions, often with different muscles performing different types
of contractions, but also with some muscles performing different
types of contractions during different phases of the task (Dick-
inson et al., 2000; Rome, 2002). There are many studies that
demonstrate the increased energy demands and excess heat pro-
duction of isotonic relative to isometric contractions (Hill, 1938;
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FIGURE 6 | Force during 30 Hz eccentric contraction at different lengths
at a velocity of 2–12 mm/s with and without DAP. Data are expressed as
a percent of the initial pre-drug isometric twitch force. Values are
means±SE.
FIGURE 7 | Examples of load curve experiment. (A) Is an example of
the length change from L0 to +1.2 mm. After the first 300 ms of the
500 ms–30 Hz train, the muscle length was changed at a velocity of
6 mm/s. Peak force was measured while the muscle was being lengthened
and stimulated (indicated by flat line). (B) Shows the resulting change in
load after the addition of control saline. (C) Shows the resulting change in
load after the addition of DAP.
FIGURE 8 | Force during eccentric contractions of 1.2 mm at constant
velocity of 6 mm/s at different frequencies with and without DAP. Data
are expressed as a percent of the initial pre-drug isometric twitch force.
Values are means±SE.
FIGURE 9 | Force during repeated 1.2 mm 30 Hz eccentric contractions
at constant velocity of 6 mm/s with and without DAP. Values are
expressed as a percent of the initial pre-drug isometric twitch force. Values
are means±SE.
Han et al., 2003) and the damaging effect that repetitive and
excessive eccentric contractions have on muscle fibers (Asp et al.,
1995; Fluckey et al., 2001). Thus, it is important to augment
muscle force for the shortest amount of time possible to pre-
vent the least amount of muscle fiber damage from excessive
stimulation.
In the present study, maximum shortening, work, shorten-
ing velocity, and power were all increased due to DAP during
isotonic contractions. The amount of increase is difficult to com-
pare directly to the results from previous experiments due to the
different parameters used to measure the different types of con-
tractions, but nonetheless comparisons of percentage increases
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in contractile performance, as well as durations of contractile
improvements during repetitive stimulation, produced by DAP
can be informative.
In previous studies, twitch force increases of ∼75–150% were
seen during in vitro isometric contraction at optimal DAP con-
centrations in normal muscle (van Lunteren and Moyer, 1996,
1998, 2002). The duration of DAP force augmentation during iso-
metric in vitro studies was typically in the order of 2–5 min (van
Lunteren and Moyer, 1996, 1998, 2002). In situ isometric con-
traction force percent increases were similar in magnitude to the
isometric in vitro increases (van Lunteren et al., 2008). Twitch
force increased by 105% and the initial train force during 20 Hz
fatigue was elevated by 110%, staying elevated by 25% throughout
the remaining 30 min of intermittent in situ isometric contraction
stimulation. In our recent in vitro isotonic contraction experi-
ments DAP improved both work and power of the diaphragm and
fast-twitch leg muscle (van Lunteren and Pollarine, 2010). These
increases occurred throughout the various loads tested, but were
greatest at 60% load. For the EDL, work increased by∼200% and
power increased by∼500%.
In the current study, DAP increased in situ isotonic contractions
similar to the previous studies as evident by a 200% maximum
increase in power at 90% load and a 600% increase in work at
100% load. At the onset of the fatigue run, DAP increased maxi-
mum shortening by 150%, work by 115% and shortening velocity,
and power by 40% each. These increases became smaller through-
out the 300 train stimulation period and approached the levels of
untreated muscles by the end of the 7.5 min protocol.
DAP increased muscle force during lengthening contractions
by a maximum of 85% during the lengthening curve. There have
been no eccentric EDL muscle contraction studies done in vitro or
in situ with DAP to compare to the present study. However, this
is comparable to the large force increases seen in isometric in situ
contractions. During fatigue, the initial force was ∼100% higher
with DAP, however this force quickly decreased and fell below
that of untreated muscles after less than a minute of stimulation,
in contrast to both isometric and isotonic fatiguing contractions
during which contractile performance of DAP-treated muscle
never declined below that of untreated muscle (van Lunteren et al.,
2008; van Lunteren and Pollarine, 2010).
Blood pressure was not monitored during this experiment, and
it is possible that blood pressure or more importantly blood flow
are altered by DAP in the dose we used. Alterations in blood pres-
sure or blood flow could contribute to the beneficial effects of
DAP. However, DAP was also found previously to increase muscle
performance in vitro (van Lunteren and Moyer, 1996, 1998; van
Lunteren et al., 2006, 2008; Ionno et al., 2008; van Lunteren and
Pollarine, 2010), indicating that DAP has substantial direct effects
independent of blood flow.
In conclusion, DAP augments both isotonic and eccentric EDL
muscle contraction in situ similar to previous in vitro studies.
However, these increases were not as long-lasting as the increases
seen during in situ isometric contractions during the course of
fatigue-inducing contractions. Perhaps the extra energy required
for isotonic contractions and the muscle damage that occurs dur-
ing eccentric contraction prevent these increases from lasting as
robustly throughout the course of stimulation as was seen pre-
viously with isometric contractions (van Lunteren and Moyer,
1996, 1998, 2002). The difference in the amount of eccentric con-
traction muscle damage between DAP-treated and control muscle
was not measured. The effects of DAP on the amount of protec-
tion to this injury is a subject worthy of future experimentation.
The benefits of DAP treatment are greater during isometric and
isotonic contractions, however there is still force augmentation
during eccentric contractions. The benefit during eccentric con-
tractions is early and vanishes as the muscle becomes fatigued.
It is clear from these results that DAP-induced augmentation of
contractile force is still effective during isotonic and eccentric con-
tractions and will have potential therapeutic value in functional
electrical stimulation applications.
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APPENDIX
Table A1 | Force (in grams) during 30 Hz eccentric contraction at
different lengths at a velocity of 2–12 mm/s, during eccentric
contractions of 1.2 mm at constant velocity of 6 mm/s at different
frequencies and during repeated 1.2 mm 30 Hz eccentric contractions
at constant velocity of 6 mm/s with and without DAP.
No drug DAP
Lengthening (mm)
2 150±23 194±19
4 193±27 260±20
6 214±27 295±19
8 227±28 314±20
10 239±28 326±20
12 256±27 335±21
Frequency (Hz)
5 78±7 113±8
10 73±6 110±8
20 83±8 121±9
25 141±35 182±24
30 208±23 286±23
35 270±27 320±24
40 318±22 352±21
50 365±22 369±22
60 390±22 373±23
70 411±26 362±30
Fatigue (s)
1 166±19 274±18
10 264±37 285±6
20 297±38 292±8
30 296±36 271±5
40 285±32 234±8
50 261±25 196±12
60 227±20 171±12
70 193±16 155±11
80 167±15 141±10
90 145±14 128±8
100 129±14 116±7
110 115±14 105±5
120 103±13 102±8
130 93±12 94±7
140 86±11 88±6
150 78±10 82±4
160 73±9 77±4
170 68±8 73±3
180 64±7 69±3
190 59±7 67±2
200 58±7 66±3
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